KR960700727A - 호르몬 대체 치료(hormone replacement therapy) - Google Patents

호르몬 대체 치료(hormone replacement therapy) Download PDF

Info

Publication number
KR960700727A
KR960700727A KR1019950703613A KR19950703613A KR960700727A KR 960700727 A KR960700727 A KR 960700727A KR 1019950703613 A KR1019950703613 A KR 1019950703613A KR 19950703613 A KR19950703613 A KR 19950703613A KR 960700727 A KR960700727 A KR 960700727A
Authority
KR
South Korea
Prior art keywords
antiprogestin
estrogen
kit
amount
administration
Prior art date
Application number
KR1019950703613A
Other languages
English (en)
Other versions
KR100248857B1 (ko
Inventor
그래이 디이. 허드겐
Original Assignee
데이비드 이. 디얼
헴프톤로드 메디칼칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21816657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960700727(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 데이비드 이. 디얼, 헴프톤로드 메디칼칼리지 filed Critical 데이비드 이. 디얼
Publication of KR960700727A publication Critical patent/KR960700727A/ko
Application granted granted Critical
Publication of KR100248857B1 publication Critical patent/KR100248857B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

여성에 있어서 에스트로젠이 유도된 자궁내막의 증식을 억제하는 안티프로제스틴양과 함께 에스트로젠을 투여하는 호르몬 대체 치료 방법.

Description

호르몬 대체 치료(HORMONE REPLACEMENT THERAPY)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. 프로제스틴 투여가 없는 상태에서, 안티프로제스틴의 에스트로겐이 유도된 자궁내막의 증식을 억제하기 위해서 유효한 안티프로제스틴의 양과 호르몬 대체 치료 유효량의 에스트로겐을, 이러한 치료를 필요로 하는 여성에게 투여하는 호르몬 대체 치료방법.
  2. 제1항에 있어서, 안티프로제스틴이 매일 투여되는 방법.
  3. 제2항에 있어서, 투여방법은 경구투여인 방법.
  4. 제1항에 있어서, 에스트로젠 및 안티프로제스틴이 매일 투여되는 방법.
  5. 제1항에 있어서, 투여방법은 경구투여인 방법.
  6. 제1항에 있어서, 각각의 투여에 있어서 안티프로제스틴 약 0.5~10㎎을 매일 투여하는 방법.
  7. 제6항에 있어서, 그 약 1~5㎎인 방법.
  8. 제1항에 있어서, 투약의 형태가 저장부에 의한 방법.
  9. 제1항에 있어서, 안티프제스틴이 프로제스틴 수용체 길항약인 방법.
  10. 제9항에 있어서, 안티프로제스틴이 RU 486인 방법
  11. 제1항에 있어서, 안티프로제스테론의 투여양은 실질적인 무월경상태를 초래하기에 충분한 방법.
  12. 제1항에 있어서, 안티프로제스틴의 투여양은 투여된 에스트로젠의 뼈대보호 효과를 보전하는 방법.
  13. 프로제스틴 투여가 없는 상태에서 이러한 치료를 필요로 하는 여성에게 에스트로젠이 투여되는 호르몬 대체 치료 방법에 있어서, 에스트로젠이 유도된 자궁내막의 증식을 억제하는 양의 안티프로제스틴이 상기한 여성에게 추가 투여되는 개량.
  14. 에스트로젠이 유도된 자궁내막의 증식을 억제하는 안티프로제스틴의 양을 함유하는 부분과 에스트로젠의 호르몬 대체 치료유효량을 함유하는 부분인 복수의 정제를 포함하는 키트.
  15. 제14항에 있어서, 각각의 정제는 에스트로젠 및 안티프로제스틴을 모두 함유하는 키트.
  16. 제15항에 있어서, 안티프로제스틴의 양이 약 0.5~10㎎인 키트.
  17. 제16항에 있어서, 안티프로제스틴의 양이 약 1~5㎎인 키트.
  18. 제17항에 있어서, 안티프로제스틴이 RU 486인 키트.
  19. 제14항에 있어서, 안티프로제스틴의 양이 약 0.5~10인 키트.
  20. 제14항에 있어서, 안티프로제스틴의 양이 약 1~5㎎인 키트.
  21. 제14항에 있어서, 안티프로제스틴이 프로제스틴 수용체 길항약인 키트.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950703613A 1993-02-25 1994-02-18 호르몬 대체치료 KR100248857B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8/023692 1993-02-25
US08/023,692 US5468736A (en) 1993-02-25 1993-02-25 Hormone replacement therapy
US08/023,692 1993-02-25
PCT/US1994/001815 WO1994018983A1 (en) 1993-02-25 1994-02-18 Hormone replacement therapy

Publications (2)

Publication Number Publication Date
KR960700727A true KR960700727A (ko) 1996-02-24
KR100248857B1 KR100248857B1 (ko) 2000-04-01

Family

ID=21816657

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950703613A KR100248857B1 (ko) 1993-02-25 1994-02-18 호르몬 대체치료

Country Status (25)

Country Link
US (1) US5468736A (ko)
EP (1) EP0686037B1 (ko)
JP (1) JP3441459B2 (ko)
KR (1) KR100248857B1 (ko)
AT (1) ATE202281T1 (ko)
AU (1) AU680239B2 (ko)
BG (1) BG62383B1 (ko)
BR (1) BR9406667A (ko)
CA (1) CA2157003C (ko)
CZ (1) CZ290562B6 (ko)
DE (1) DE69427529T2 (ko)
DK (1) DK0686037T3 (ko)
ES (1) ES2159552T3 (ko)
FI (1) FI953926A (ko)
GR (1) GR3036649T3 (ko)
HU (1) HU221169B1 (ko)
NO (1) NO309456B1 (ko)
NZ (1) NZ262657A (ko)
PL (1) PL176796B1 (ko)
PT (1) PT686037E (ko)
RO (1) RO115115B1 (ko)
RU (1) RU2139056C1 (ko)
SK (1) SK282921B6 (ko)
UA (1) UA43842C2 (ko)
WO (1) WO1994018983A1 (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
AU5942700A (en) * 1996-03-11 2000-11-30 Schering Aktiengesellschaft Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US20060014728A1 (en) * 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
IL148417A0 (en) * 1999-08-31 2002-09-12 Jenapharm Gmbh Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
US6432643B1 (en) 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
DK1390040T3 (da) * 2001-05-18 2007-04-23 Pantarhei Bioscience Bv Farmaceutisk præparat til anvendelse i hormonerstatningsterapi
US7871995B2 (en) * 2001-05-23 2011-01-18 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2002094279A1 (en) * 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ES2278925T3 (es) * 2001-11-15 2007-08-16 Pantarhei Bioscience B.V. Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal.
DE10206089A1 (de) 2002-02-13 2002-08-14 Zimmer Ag Bersteinsatz
ATE340579T1 (de) * 2002-06-11 2006-10-15 Pantarhei Bioscience Bv Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung
AU2003274941A1 (en) * 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
AU2003253506A1 (en) * 2002-07-12 2004-02-02 Pantarhei Biosciences B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
PT1556058E (pt) * 2002-10-23 2008-03-20 Pantarhei Bioscience Bv Composições farmacêuticas que compreendem derivados do estretol para serem utilizadas no tratamento do cancro
EP1624878B1 (en) * 2003-05-22 2006-09-27 Pantarhei Bioscience B.V. Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain
HUE051484T2 (hu) 2006-10-24 2021-03-01 Allergan Pharmaceuticals Int Ltd Készítmények és eljárások az endometriális proliferációk elnyomására
WO2008085038A2 (en) * 2007-01-08 2008-07-17 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US9850273B2 (en) * 2014-12-03 2017-12-26 Evestra, Inc. Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
EP3701944B1 (en) 2015-06-18 2021-12-08 Estetra SRL Orodispersible dosage unit containing an estetrol component
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890356A (en) * 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US3928398A (en) * 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4416822A (en) * 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
AU572589B2 (en) * 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
EP0686037A4 (en) 1997-11-26
JP3441459B2 (ja) 2003-09-02
SK104995A3 (en) 1997-04-09
KR100248857B1 (ko) 2000-04-01
BG62383B1 (bg) 1999-10-29
JPH08510993A (ja) 1996-11-19
NO953243D0 (no) 1995-08-17
RU2139056C1 (ru) 1999-10-10
GR3036649T3 (en) 2001-12-31
UA43842C2 (uk) 2002-01-15
PL176796B1 (pl) 1999-07-30
WO1994018983A1 (en) 1994-09-01
CA2157003A1 (en) 1994-09-01
CZ290562B6 (cs) 2002-08-14
BR9406667A (pt) 1996-01-23
NZ262657A (en) 1997-05-26
ES2159552T3 (es) 2001-10-16
FI953926A0 (fi) 1995-08-22
NO953243L (no) 1995-08-17
HUT72080A (en) 1996-03-28
SK282921B6 (sk) 2003-01-09
BG99880A (bg) 1996-02-28
CA2157003C (en) 2001-04-17
DE69427529D1 (de) 2001-07-26
ATE202281T1 (de) 2001-07-15
US5468736A (en) 1995-11-21
PT686037E (pt) 2001-09-28
AU6245494A (en) 1994-09-14
PL310660A1 (en) 1995-12-27
NO309456B1 (no) 2001-02-05
RO115115B1 (ro) 1999-11-30
DK0686037T3 (da) 2001-08-27
DE69427529T2 (de) 2001-11-22
CZ204895A3 (en) 1996-03-13
HU9502306D0 (en) 1995-09-28
FI953926A (fi) 1995-08-22
HU221169B1 (en) 2002-08-28
EP0686037A1 (en) 1995-12-13
AU680239B2 (en) 1997-07-24
EP0686037B1 (en) 2001-06-20

Similar Documents

Publication Publication Date Title
KR960700727A (ko) 호르몬 대체 치료(hormone replacement therapy)
RU95118436A (ru) Гормональная заместительная терапия
UA48973C2 (uk) Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
RU2245713C2 (ru) Прерывистая гормонозаместительная терапия низкими дозами эстрогена
KR960706344A (ko) 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne)
NO986104D0 (no) Progesteron-anti-progesteron regimer
DK0499348T3 (da) Ovulationshæmmende middel til hormonal kontraception
AU5587690A (en) Treatment of postmenopausal disorders
US3795734A (en) Cyclic regimen of hormone administration for contraception
UA41401C2 (uk) Фармацевтичний контрацептивний комбінований препарат
HUP9904344A2 (hu) Egyfázisú fogamzásgátló eljárás és progesztin és ösztrogén kombinációját tartalmazó kit
KR920011514A (ko) 프로게스토겐만을 함유하는 피임제
HUP9900612A2 (hu) Új hormonális gyógyászati készítmények, valamint a készítmények alkalmazása ösztrogénpótlásra
MX9304931A (es) Anticonceptivos que contienen antiprogestogenos.
NZ504351A (en) Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen
CA2444980A1 (en) Single dose aromatase inhibitor for treating infertility
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
JP2004529924A5 (ko)
KR960700726A (ko) 수정의 방지 또는 억제방법(method of preventing of inhibting fertilization)
GB1214712A (en) Contraceptive preparations
TH27339A (th) ฮอร์โมนตัวใหม่ที่ใช้เป็นยาและประโยชน์ของมันในการรักษาภาวะขาดเอสโตเจน
AR002283A1 (es) Composiciones para inyectar una vez al mes, que constituye un medicamento anticonceptivo de accion prolongada, apta para la terapia de reemplazo dehormonas en mujeres perimenopausicas y premonopausicas.
JO2213B1 (en) A pharmaceutical composition for use as a contraceptive method
MX9703018A (es) Antagonistas de progesterona competentes para regular la fertilidad femenina segun se requiera.
GB1254893A (en) Therapeutic composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110607

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20120423

Year of fee payment: 15

EXPY Expiration of term